Elisabeth Bacon
Research Subjects
Research Interests
Elisabeth Bacon has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Marie Danion
Psychiatry Service I, Inserm 666 Unit, 67091 Strasbourg, France
3 shared publications Marie Izaute
2 shared publicationsAgnes Bruant
INSERM Unité 405, Département de Psychiatrie d’Adultes, Hôpitaux Universitaires, 1 place de l’Hôpital, BP 426, F-67091 Strasbourg Cedex, France, Fax: +33-3-88 11 64 46
1 shared publicationB. Schwartz
1 shared publicationBennett L. Schwartz
1 shared publicationDanielle Grange
Centre National Universitaire Sud de Calcul, 950 rue de Saint Priest, BP 7229, F-34184 Montpellier Cedex 4, France
1 shared publication
Latest Publications
- 31 December 2011
- Published by Elsevier in Consciousness and Cognition
- Vol. 20 (4) , 1315-1326
Metamemory knowledge and beliefs in patients with schizophrenia and how these relate to objective cognitive abilities
- 31 December 2011
- Published by Elsevier in Consciousness and Cognition
- Vol. 20 (4) , 1315-1326
Metamemory knowledge and beliefs in patients with schizophrenia and how these relate to objective cognitive abilities
- 30 August 2010
- Published by Springer Nature
- p. 81-104
Further Insight into Cognitive and Metacognitive Processes of the Tip-of-the-Tongue State with an Amnesic Drug as Cognitive Tool
- 30 August 2010
- Published by Springer Nature
- p. 81-104
Further Insight into Cognitive and Metacognitive Processes of the Tip-of-the-Tongue State with an Amnesic Drug as Cognitive Tool
- 1 December 2009
- Published by Elsevier in Biological Psychiatry
- Vol. 66 (11) , 1031-1037
Metacognition in Schizophrenia: Processes Underlying Patients' Reflections on Their Own Episodic Memory
- 1 December 2009
- Published by Elsevier in Biological Psychiatry
- Vol. 66 (11) , 1031-1037
Metacognition in Schizophrenia: Processes Underlying Patients' Reflections on Their Own Episodic Memory
- 29 February 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 98, 23-24
What do patients with schizophrenia know when they cannot remember?
- 29 February 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 98, 23-24
What do patients with schizophrenia know when they cannot remember?
- 1 January 2008
- Published by OpenEdition
- p. 99-115
Contribution des recherches en psychopharmacologie à la compréhension du fonctionnement de la mémoire normale et pathologique : effets d’une molécule amnésiante sur le phénomène du « mot sur le bout de la langue »
Les benzodiazépines, qui induisent des amnésies transitoires, peuvent être utilisées comme outils pour explorer les mécanismes de la mémoire, normale ou pathologique. Avec le lorazépam, notamment, on peut provoquer expérimentalement une amnésie soit temporaire (dans le cas de la mémoire épisodique), soit réversible (pour la mémoire sémantique). Nous avons étudié les effets du lorazépam sur un trouble de mémoire banal qui affecte occasionnellement les sujets sains : « le mot sur le bout de la langue » (MBL). Cette situation cognitive très particulière est caractérisée par une dissociation entre l’état cognitif, c’est-à-dire l’incapacité à produire une information connue, et l’état métacognitif à savoir la conviction intense de connaître néanmoins cette information. Avec un questionnaire de culture générale, nous avons pu observer que le lorazépam augmente la fréquence de la dissociation temporelle entre la composante cognitive et celle du ressenti subjectif, du processus du mot sur le bout de la langue. En effet, les sujets sous lorazépam sont plus fréquemment dans la situation dite de « MBL substitution » : il y a inaccessibilité transitoire d’une information connue, production d’un mot proche de la bonne réponse, mais sans que les sujets ressentent l’imminence de la récupération de la bonne réponse. Les sujets produisent donc une réponse incorrecte et ne ressentent l’expérience subjective du mot sur le bout de la langue qu’après avoir été informés de leur erreur. L’effet anxiolytique et anticonflit de la benzodiazépine semble précisément impliqué dans la façon dont les sujets ressentent (ou ne ressentent pas) le conflit entre l’incapacité provisoire d’accéder à une information en mémoire et la perception intense et aiguë de l’existence de cette information. Cette illusion sémantique pourrait constituer une des explications à la perturbation de la mémoire sémantique sous l’effet du lorazépam. Elle pourrait aussi être à l’origine d’un certain nombre de troubles de mémoire observés dans les amnésies organiques.
- 1 January 2008
- Published by OpenEdition
- p. 99-115
Contribution des recherches en psychopharmacologie à la compréhension du fonctionnement de la mémoire normale et pathologique : effets d’une molécule amnésiante sur le phénomène du « mot sur le bout de la langue »
Les benzodiazépines, qui induisent des amnésies transitoires, peuvent être utilisées comme outils pour explorer les mécanismes de la mémoire, normale ou pathologique. Avec le lorazépam, notamment, on peut provoquer expérimentalement une amnésie soit temporaire (dans le cas de la mémoire épisodique), soit réversible (pour la mémoire sémantique). Nous avons étudié les effets du lorazépam sur un trouble de mémoire banal qui affecte occasionnellement les sujets sains : « le mot sur le bout de la langue » (MBL). Cette situation cognitive très particulière est caractérisée par une dissociation entre l’état cognitif, c’est-à-dire l’incapacité à produire une information connue, et l’état métacognitif à savoir la conviction intense de connaître néanmoins cette information. Avec un questionnaire de culture générale, nous avons pu observer que le lorazépam augmente la fréquence de la dissociation temporelle entre la composante cognitive et celle du ressenti subjectif, du processus du mot sur le bout de la langue. En effet, les sujets sous lorazépam sont plus fréquemment dans la situation dite de « MBL substitution » : il y a inaccessibilité transitoire d’une information connue, production d’un mot proche de la bonne réponse, mais sans que les sujets ressentent l’imminence de la récupération de la bonne réponse. Les sujets produisent donc une réponse incorrecte et ne ressentent l’expérience subjective du mot sur le bout de la langue qu’après avoir été informés de leur erreur. L’effet anxiolytique et anticonflit de la benzodiazépine semble précisément impliqué dans la façon dont les sujets ressentent (ou ne ressentent pas) le conflit entre l’incapacité provisoire d’accéder à une information en mémoire et la perception intense et aiguë de l’existence de cette information. Cette illusion sémantique pourrait constituer une des explications à la perturbation de la mémoire sémantique sous l’effet du lorazépam. Elle pourrait aussi être à l’origine d’un certain nombre de troubles de mémoire observés dans les amnésies organiques.
- 30 June 2007
- Published by Elsevier in Consciousness and Cognition
- Vol. 16 (2) , 360-373
Dissociation between the cognitive process and the phenomenological experience of TOT: Effect of the anxiolytic drug lorazepam on TOT states
- 30 June 2007
- Published by Elsevier in Consciousness and Cognition
- Vol. 16 (2) , 360-373
Dissociation between the cognitive process and the phenomenological experience of TOT: Effect of the anxiolytic drug lorazepam on TOT states
- 2 February 2007
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 13 (2) , 219-227
Preserved memory monitoring but impaired memory control during episodic encoding in patients with schizophrenia
Metamemory awareness refers to the ability to monitor and control how well information is processed depending on the loads and needs of the task at hand. There is some evidence that metamemory functions are impaired in schizophrenia at the time of memory retrieval. This study investigated whether patients with schizophrenia exhibit metamemory abnormalities during the encoding of new information. The frequency of item presentation was varied. Both memory control and memory monitoring were assessed using study-time allocation and Judgments of Learning (JOL), respectively. Repeated items were recalled better by both groups, but memory performance was lower in patients than controls. Patients' behavior patterns were abnormal in terms of the study-time allocated for each item according to presentation frequency. Patients' JOLs were lower than those of controls but remained sensitive to item repetition. Patients' predictive values on memory accuracy were no different to those measured in controls. In addition, none of the patients reported using efficient strategies to help memorize target items. The results show a dissociation between memory control, which was impaired, and memory monitoring, which was spared, in patients with schizophrenia during encoding of new information (JINS, 2007, 13, 219–227.)
- 2 February 2007
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 13 (2) , 219-227
Preserved memory monitoring but impaired memory control during episodic encoding in patients with schizophrenia
Metamemory awareness refers to the ability to monitor and control how well information is processed depending on the loads and needs of the task at hand. There is some evidence that metamemory functions are impaired in schizophrenia at the time of memory retrieval. This study investigated whether patients with schizophrenia exhibit metamemory abnormalities during the encoding of new information. The frequency of item presentation was varied. Both memory control and memory monitoring were assessed using study-time allocation and Judgments of Learning (JOL), respectively. Repeated items were recalled better by both groups, but memory performance was lower in patients than controls. Patients' behavior patterns were abnormal in terms of the study-time allocated for each item according to presentation frequency. Patients' JOLs were lower than those of controls but remained sensitive to item repetition. Patients' predictive values on memory accuracy were no different to those measured in controls. In addition, none of the patients reported using efficient strategies to help memorize target items. The results show a dissociation between memory control, which was impaired, and memory monitoring, which was spared, in patients with schizophrenia during encoding of new information (JINS, 2007, 13, 219–227.)
- 27 July 1998
- Published by Springer Nature in Psychopharmacology
- Vol. 138 (3-4) , 318-325
Confidence level and feeling of knowing for episodic and semantic memory: an investigation of lorazepam effects on metamemory
The effects of lorazepam (0.026 or 0.038 mg/kg), a benzodiazepine, and of a placebo on metamemory, i.e. knowledge about one’s own memory capabilities, were investigated in 36 healthy volunteers. Accuracy of confidence levels (CL) in the correctness of recalled answers and accuracy of feeling of knowing (FOK) the answers when recall fails were measured using a sentence memory task assessing episodic memory and a task consisting of general information questions and assessing semantic memory. Lorazepam impaired episodic memory. Unexpectedly, it also impaired performance in both the recall and recognition phases of the task assessing semantic memory, suggesting that it decreased the ability to distinguish between correct and incorrect information. In episodic memory, lorazepam 0.038 mg/kg-treated subjects exhibited an impaired CL accuracy, compared to placebo-treated subjects, and their FOK accuracy was at chance. In semantic memory, their overall CL and FOK accuracy was apparently spared. However, these subjects selectively overestimated their CL judgements for incorrect answers; moreover, secondary analyses showed that FOK accuracy for a subset of low-accuracy items was virtually nil. These results suggest that lorazepam impairs metamemory for both episodic and semantic memory.
- 27 July 1998
- Published by Springer Nature in Psychopharmacology
- Vol. 138 (3-4) , 318-325
Confidence level and feeling of knowing for episodic and semantic memory: an investigation of lorazepam effects on metamemory
The effects of lorazepam (0.026 or 0.038 mg/kg), a benzodiazepine, and of a placebo on metamemory, i.e. knowledge about one’s own memory capabilities, were investigated in 36 healthy volunteers. Accuracy of confidence levels (CL) in the correctness of recalled answers and accuracy of feeling of knowing (FOK) the answers when recall fails were measured using a sentence memory task assessing episodic memory and a task consisting of general information questions and assessing semantic memory. Lorazepam impaired episodic memory. Unexpectedly, it also impaired performance in both the recall and recognition phases of the task assessing semantic memory, suggesting that it decreased the ability to distinguish between correct and incorrect information. In episodic memory, lorazepam 0.038 mg/kg-treated subjects exhibited an impaired CL accuracy, compared to placebo-treated subjects, and their FOK accuracy was at chance. In semantic memory, their overall CL and FOK accuracy was apparently spared. However, these subjects selectively overestimated their CL judgements for incorrect answers; moreover, secondary analyses showed that FOK accuracy for a subset of low-accuracy items was virtually nil. These results suggest that lorazepam impairs metamemory for both episodic and semantic memory.
- 1 January 1994
- Vol. 150 (5) , 330-7
[Memory and benzodiazepines].
Benzodiazepines (BZs) affect acquisition of new information, while retrieval of already learned information is unimpaired. The variability of this effect is important and depends on the nature of the BZ, its dose, the route of administration and the susceptibility of the subject taking the drug. This last factor depends itself on the anxiety level, the age, and a less known idiosyncratic susceptibility of the patient. Finally, there is probably a partial tolerance for the amnestic action of BZs, which explains the fact that the most dramatic amnesias have been described after administration of a single dose of BZ, taken by a patient unaccustomed to BZs. The value of pharmacocinetic and pharmacodynamic characteristics in predicting cognitive impairment remains misunderstood, even though in clinical practice the greatest amnestic effects have been described with short-acting BZs. The interest of studying BZs induced amnesia rely upon several arguments: first, it can be an harmful side-effect, which could be avoided or at least predicted by a better knowledge of BZs and the synthesis of new and more specific drugs; secondly it is an interesting model of organic amnesia, which could allow a better understanding of normal memory.
- 1 January 1994
- Vol. 150 (5) , 330-7
[Memory and benzodiazepines].
Benzodiazepines (BZs) affect acquisition of new information, while retrieval of already learned information is unimpaired. The variability of this effect is important and depends on the nature of the BZ, its dose, the route of administration and the susceptibility of the subject taking the drug. This last factor depends itself on the anxiety level, the age, and a less known idiosyncratic susceptibility of the patient. Finally, there is probably a partial tolerance for the amnestic action of BZs, which explains the fact that the most dramatic amnesias have been described after administration of a single dose of BZ, taken by a patient unaccustomed to BZs. The value of pharmacocinetic and pharmacodynamic characteristics in predicting cognitive impairment remains misunderstood, even though in clinical practice the greatest amnestic effects have been described with short-acting BZs. The interest of studying BZs induced amnesia rely upon several arguments: first, it can be an harmful side-effect, which could be avoided or at least predicted by a better knowledge of BZs and the synthesis of new and more specific drugs; secondly it is an interesting model of organic amnesia, which could allow a better understanding of normal memory.